Gavish-Galilee Bio Applications Ltd.
|Gavish-Galilee Bio Applications Ltd. Patent applications|
|Patent application number||Title||Published|
|20140042100||METHOD FOR PRETREATMENT OF WASTEWATER AND RECREATIONAL WATER WITH NANOCOMPOSITES - A single step pretreatment of wastewater or recreational water is provided comprising treatment with nanocomposites consisting of an anchoring particle such as a clay mineral and one or more polymers.||02-13-2014|
|20120208879||METHODS AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING PSORIASIS - Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.||08-16-2012|
|20120156227||PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT - A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination||06-21-2012|
|20080286312||Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes - The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and/or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the β2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.||11-20-2008|
|20080213237||Antigen Specific Lymphocytes, Compositions Thereof, and Methods for Isolation and Preparation Thereof - The invention relates to a method for the isolation of T cell lymphocyte, preferably, CD8||09-04-2008|
Patent applications by Gavish-Galilee Bio Applications Ltd.